Literature DB >> 23644875

Enoxacin inhibits growth of prostate cancer cells and effectively restores microRNA processing.

Elsa Sousa1, Inês Graça, Tiago Baptista, Filipa Q Vieira, Carlos Palmeira, Rui Henrique, Carmen Jerónimo.   

Abstract

Prostate cancer (PCa) is one of the most incident malignancies worldwide. Although efficient therapy is available for early-stage PCa, treatment of advanced disease is mainly ineffective and remains a clinical challenge. microRNA (miRNA) dysregulation is associated with PCa development and progression. In fact, several studies have reported a widespread downregulation of miRNAs in PCa, which highlights the importance of studying compounds capable of restoring the global miRNA expression. The main aim of this study was to define the usefulness of enoxacin as an anti-tumoral agent in PCa, due to its ability to induce miRNA biogenesis in a TRBP-mediated manner. Using a panel of five PCa cell lines, we observed that all of them were wild type for the TARBP2 gene and expressed TRBP protein. Furthermore, primary prostate carcinomas displayed normal levels of TRBP protein. Remarkably, enoxacin was able to decrease cell viability, induce apoptosis, cause cell cycle arrest, and inhibit the invasiveness of cell lines. Enoxacin was also effective in restoring the global expression of miRNAs. This study is the first to show that PCa cells are highly responsive to the anti-tumoral effects of enoxacin. Therefore, enoxacin constitutes a promising therapeutic agent for PCa.

Entities:  

Keywords:  TRBP; enoxacin; microRNAs; prostate cancer; therapy

Mesh:

Substances:

Year:  2013        PMID: 23644875      PMCID: PMC3741225          DOI: 10.4161/epi.24519

Source DB:  PubMed          Journal:  Epigenetics        ISSN: 1559-2294            Impact factor:   4.528


  44 in total

Review 1.  MicroRNAs: small RNAs with a big role in gene regulation.

Authors:  Lin He; Gregory J Hannon
Journal:  Nat Rev Genet       Date:  2004-07       Impact factor: 53.242

Review 2.  The widespread regulation of microRNA biogenesis, function and decay.

Authors:  Jacek Krol; Inga Loedige; Witold Filipowicz
Journal:  Nat Rev Genet       Date:  2010-07-27       Impact factor: 53.242

Review 3.  The therapeutic potential of microRNAs: disease modulators and drug targets.

Authors:  Ailbhe M McDermott; Helen M Heneghan; Nicola Miller; Michael J Kerin
Journal:  Pharm Res       Date:  2011-08-05       Impact factor: 4.200

Review 4.  Epigenetics in prostate cancer: biologic and clinical relevance.

Authors:  Carmen Jerónimo; Patrick J Bastian; Anders Bjartell; Giuseppina M Carbone; James W F Catto; Susan J Clark; Rui Henrique; William G Nelson; Shahrokh F Shariat
Journal:  Eur Urol       Date:  2011-06-22       Impact factor: 20.096

5.  MBP-1 upregulates miR-29b that represses Mcl-1, collagens, and matrix-metalloproteinase-2 in prostate cancer cells.

Authors:  Robert Steele; Justin L Mott; Ratna B Ray
Journal:  Genes Cancer       Date:  2010-04-01

Review 6.  Molecular genetics of prostate cancer: new prospects for old challenges.

Authors:  Michael M Shen; Cory Abate-Shen
Journal:  Genes Dev       Date:  2010-09-15       Impact factor: 11.361

7.  Widespread deregulation of microRNA expression in human prostate cancer.

Authors:  M Ozen; C J Creighton; M Ozdemir; M Ittmann
Journal:  Oncogene       Date:  2007-09-24       Impact factor: 9.867

8.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

Authors:  Ian F Tannock; Ronald de Wit; William R Berry; Jozsef Horti; Anna Pluzanska; Kim N Chi; Stephane Oudard; Christine Théodore; Nicholas D James; Ingela Turesson; Mark A Rosenthal; Mario A Eisenberger
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245

9.  SIRT1 is significantly elevated in mouse and human prostate cancer.

Authors:  Derek M Huffman; William E Grizzle; Marcas M Bamman; Jeong-su Kim; Isam A Eltoum; Ada Elgavish; Tim R Nagy
Journal:  Cancer Res       Date:  2007-07-15       Impact factor: 12.701

10.  Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy.

Authors:  W Weichert; A Röske; V Gekeler; T Beckers; C Stephan; K Jung; F R Fritzsche; S Niesporek; C Denkert; M Dietel; G Kristiansen
Journal:  Br J Cancer       Date:  2008-01-22       Impact factor: 7.640

View more
  27 in total

Review 1.  The role of TARBP2 in the development and progression of cancers.

Authors:  Xin Yu; Zheng Li
Journal:  Tumour Biol       Date:  2015-10-20

2.  Bis-enoxacin inhibits bone resorption and orthodontic tooth movement.

Authors:  E J Toro; J Zuo; A Gutierrez; A Guiterrez; R L La Rosa; A J Gawron; V Bradaschia-Correa; V Arana-Chavez; C Dolce; M F Rivera; L Kesavalu; I Bhattacharyya; J K Neubert; L S Holliday
Journal:  J Dent Res       Date:  2013-08-19       Impact factor: 6.116

Review 3.  Role of epithelial mesenchymal transition in prostate tumorigenesis.

Authors:  Mohammad Imran Khan; Abid Hamid; Vaqar Mustafa Adhami; Rahul K Lall; Hasan Mukhtar
Journal:  Curr Pharm Des       Date:  2015       Impact factor: 3.116

Review 4.  Quinolones as a Potential Drug in Genitourinary Cancer Treatment-A Literature Review.

Authors:  Tomasz Kloskowski; Sylwia Frąckowiak; Jan Adamowicz; Kamil Szeliski; Marta Rasmus; Tomasz Drewa; Marta Pokrywczyńska
Journal:  Front Oncol       Date:  2022-06-08       Impact factor: 5.738

5.  Enoxacin Shows Broad-Spectrum Antiviral Activity against Diverse Viruses by Enhancing Antiviral RNA Interference in Insects.

Authors:  Bao Lyu; Chang Wang; Yuanyuan Bie; Jing Kong; An Wang; Liang Jin; Yang Qiu; Xi Zhou
Journal:  J Virol       Date:  2021-12-15       Impact factor: 6.549

6.  Enrofloxacin enhances the effects of chemotherapy in canine osteosarcoma cells with mutant and wild-type p53.

Authors:  D York; S S Withers; K D Watson; K W Seo; R B Rebhun
Journal:  Vet Comp Oncol       Date:  2016-06-23       Impact factor: 2.613

7.  In silico analysis suggests the RNAi-enhancing antibiotic enoxacin as a potential inhibitor of SARS-CoV-2 infection.

Authors:  Amirhossein Ahmadi; Sharif Moradi
Journal:  Sci Rep       Date:  2021-05-13       Impact factor: 4.379

8.  A New Tool for in vivo Manipulation of Brain microRNA Levels: The Work of Smalheiser et al. (2014).

Authors:  Don A Baldwin
Journal:  Front Psychiatry       Date:  2015-04-20       Impact factor: 4.157

9.  Bis-enoxacin blocks rat alveolar bone resorption from experimental periodontitis.

Authors:  Mercedes F Rivera; Sasanka S Chukkapalli; Irina M Velsko; Ju-Youn Lee; Indraneel Bhattacharyya; Calogero Dolce; Edgardo J Toro; L Shannon Holliday; Lakshmyya Kesavalu
Journal:  PLoS One       Date:  2014-03-17       Impact factor: 3.240

10.  Enoxacin Elevates MicroRNA Levels in Rat Frontal Cortex and Prevents Learned Helplessness.

Authors:  Neil R Smalheiser; Hui Zhang; Yogesh Dwivedi
Journal:  Front Psychiatry       Date:  2014-02-10       Impact factor: 4.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.